It’s been a big week for interesting stories, as the annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) has just concluded. The conference offered much to engage healthcare professionals and researchers, but the following are some presentations that appealed to me as a multiple sclerosis (MS) patient.
The debate continued over the risks versus the rewards of stem cell transplants. Joachim Burman, MD, PhD, a researcher at Uppsala University in Sweden, made the case as to why autologous hematopoietic stem cell transplantation may be the most effective MS treatment so far, and why it should be made widely available. A single administration can yield prolonged benefits, and most patients achieve “no evidence of disease activity” status for at least five years. But safety concerns exist, and the lack of control groups tempers the positive results in studies.
Stem cell therapy, or stem cell transplant, is an emerging yet controversial treatment approach for multiple sclerosis (MS). While some data uphold it as one of the most efficacious MS treatments, to date there have been no controlled studies comparing it to conventional medicines and providing more robust evidence regarding its safety and clinical benefit.
Under the topic “HSCT and stem cell treatment in MS,” a group of researchers discussed the promise and current challenges of stem cell transplant at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held Sept. 11–13 in Stockholm.
Click here to read the full story.
#ECTRIMS2019 – Remyelinating Therapy Liothyronine Well-tolerated by MS Patients, Phase 1b Trial Finds
As those of us who have multiple sclerosis know, finding a way to repair the damage to the myelin that covers our nerves would be like discovering the Holy Grail. This research, which looked into whether a potential remyelination agent is safe and might provide some repair, gives some hope.
Treatment with a potential remyelinating agent called liothyronine was safe and well-tolerated by people with multiple sclerosis (MS) in a Phase 1b trial. Preliminary results also suggested benefits in cognition, motor function, and fatigue.
The study, “A Phase 1b, open-label study to evaluate the safety and tolerability of the putative remyelinating agent, liothyronine, in individuals with multiple sclerosis,” was presented today at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), by Scott D. Newsome, professor of neurology at Johns Hopkins University School of Medicine.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?